Candesartan reduced mortality and hospital admissions in chronic heart failure

March 2004
ACP Journal Club;Mar/Apr2004, Vol. 140 Issue 2, p32
Academic Journal
The article analyses if angiotensin-receptor blocker (ARB) candesartan reduce death and hospital admissions in patients with chronic heart failure (CHF). Patients were analyzed in 618 medical centers of 26 countries. 7601 patients who were less than 18 years of age and had symptomatic CHF for about 4 weeks. Patients were stratified by site and component trial to candesartan, 4 or 8 mg once daily, doubled every 2 weeks to a target dose of 32 mg once daily. In patients with chronic heart failure (CHF), the angiotensin-receptor blocker candesartan reduced mortality and hospital admissions for worsening CHF.


Related Articles

  • Candesartan reduced mortality and hospital admissions in chronic heart failure: COMMENTARY. Pitt, Bertram // ACP Journal Club;Mar/Apr2004, Vol. 140 Issue 2, p33 

    The article comments on the study conducted to analyses the efficacy of Candesartan to reduce mortality and hospital admissions in chronic heart failure (CHF). The study extends the knowledge of the role of angiotensin-receptor blocker (ARBs) in patients with CHF. It is likely mat ARBs used at...

  • Higher volume hospitals reduce mortality in common conditions.  // PharmacoEconomics & Outcomes News;5/1/2010, Issue 602, p3 

    The article focuses on a research on the link between admission to higher volume hospitals and reduction in mortality for heart failure, acute myocardial infarction (AMI) and pneumonia in the U.S. conducted by J. S. Ross and colleagues published in the March 25, 2010 issue of the "New England...

  • Poles apart, but are they the same? A comparative study of Australian and Scottish patients with chronic heart failure. Stewart, Simon; Blue, Lynda; Capewell, Simon; Horowitz, John D.; McMurray, John J. // European Journal of Heart Failure;Mar2001, Vol. 3 Issue 2, p249 

    This paper reports on an international comparison of the characteristics, treatment and health outcomes of chronic heart failure (CHF) patients discharged from acute hospital care in Australia and Scotland. The baseline characteristics and treatment of 200 CHF patients recruited to a randomised...

  • Characterization of heart failure patients with preserved ejection fraction: a comparison between ADHERE-US registry and ADHERE-International registry. West, Ryenn; Liang, Li; Fonarow, Gregg C.; Kociol, Robb; Mills, Roger M.; O'Connor, Christopher M.; Hernandez, Adrian F. // European Journal of Heart Failure;Sep2011, Vol. 13 Issue 9, p945 

    Aims To characterize geographic differences in clinical characteristics and care of patients hospitalized with heart failure and preserved ejection fraction (HF-PEF). Methods and results Using data on 61 182 admissions in 307 US hospitals from March 2004 to March 2006 from the Acute...

  • I-PRESERVE: No reduction in mortality in patients with HF.  // Cardiology Today;Dec2008, Vol. 11 Issue 12, p1 

    The article reports that researchers for the Irbesartan in Heart Failure With Preserved Systolic Function (I-PRESERVE) study indicate that the angiotensin receptor blocker irbesartan did not reduce the risk for mortality or cardiovascular morbidity in patients with heart failure with preserved...

  • Use of Twice-Daily Exenatide in Basal Insulin--Treated Patients With Type 2 Diabetes. Buse, John B.; Bergenstal, Richard M.; Glass, Leonard C.; Heilmann, Cory R.; Lewis, Michelle S.; Kwan, Anita Y. M.; Hoogwerf, Byron J.; Rosenstock, Julio // Annals of Internal Medicine;1/18/2011, Vol. 154 Issue 2, p103 

    Background: Insulin replacement in diabetes often requires prandial intervention to reach hemoglobin A1c (HbA1c) targets. Objective: To test whether twice-daily exenatide injections reduce HbA1c levels more than placebo in people receiving insulin glargine. Design: Parallel, randomized,...

  • Beta-blockers save 7,800. Tanday, Sanjay // GP: General Practitioner;7/20/2007, p31 

    The article reports that a research conducted in Great Britain suggests that adding beta-blocker use to the quality framework could prevent 7,800 deaths from heart failure and reduce hospital admissions by nearly 10,000 annually. For the latest study, information on 437,379 heart failure...

  • n-3 polyunsaturated fatty acids and atrial fibrillation in patients with chronic heart failure: the GISSI-HF trial. Aleksova, Aneta; Masson, Serge; Maggioni, Aldo P.; Lucci, Donata; Fabbri, Gianna; Beretta, Luciano; Mos, Lucio; Paino, Anna Maria; Nicolosi, Gian Luigi; Marchioli, Roberto; Tognoni, Gianni; Tavazzi, Luigi; Sinagra, Gianfranco; Latini, Roberto // European Journal of Heart Failure;Nov2013, Vol. 15 Issue 11, p1289 

    Aims In the last few years, n-3 polyunsaturated acids (PUFAs) have been extensively studied for the prevention of AF, mostly in patients without heart failure (HF) or LV dysfunction. This post-hoc analysis of the GISSI-HF trial assessed the effect of n-3 PUFAs on AF in patients with chronic HF...

  • Impact of telemonitoring home care patients with heart failure or chronic lung disease from primary care on healthcare resource use (the TELBIL study randomised controlled trial). Martín-Lesende, Iñaki; Orruño, Estibalitz; Bilbao, Amaia; Vergara, Itziar; Carmen Cairo, M.; Bayón, Juan Carlos; Reviriego, Eva; Isabel Romo, María; Larrañaga, Jesús; Asua, José; Abad, Roberto; Recalde, Elizabete // BMC Health Services Research;2013, Vol. 13 Issue 1, p1 

    Background: There is growing evidence that home telemonitoring can be advantageous in societies with increasing prevalence of chronic diseases. The main objective of this study is to evaluate the effect of a primary care-based telemonitoring intervention on the number and length of hospital...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics